Cara Therapeutics has started dosing patients in the KALM-2 trial, a Phase lll pivotal study of KORSUVA (CR845/difelikefalin) injection to treat haemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP).

The international, multicentre, randomised, double-blind, placebo-controlled, 12-week treatment trial is expected to enrol 350 patients in the US, Europe and some countries in the Pacific Rim region.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial intends to examine the safety and efficacy of 0.5mcg/kg CR845/difelikefalin injection in the enrolled patients.

The primary efficacy objective of the KALM-2 trial is the proportion of patients achieving at least a three-point improvement from baseline with respect to the weekly mean of the daily 24‑hour worst itching intensity numeric rating scale (NRS) score at week 12.

“We will continue to focus on patient enrolment in the coming quarters and expect data readouts from both our US and global Phase lll trials in 2019.”

The trial’s secondary objectives are evaluation of itch-related quality of life changes measured using validated self-assessment 5-D Itch and Skindex-10 scales, as well as the proportion of patients obtaining greater than four-point improvement from baseline in weekly mean of the daily 24-hour worst itching intensity NRS score at week 12.

Cara Therapeutics president and CEO Derek Chalmers said: “The initiation of our second Phase lll efficacy trial in dialysis patients with CKD-aP is an important step toward our goal of developing and commercialising KORSUVA injection as a potential novel treatment option for a patient population with significant unmet medical need.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We will continue to focus on patient enrolment in the coming quarters and expect data readouts from both our US and global Phase lll trials in 2019.”

KORSUVA has previously received the breakthrough therapy designation from the US Food and Drug Administration (FDA) for use in the treatment of CKD-aP.

No approved therapies are currently available to treat the condition in the US or European Union (EU).

CKD-aP is a difficult systemic itch condition that occurs frequently and at high intensity in patients with chronic kidney disease undergoing hemodialysis and peritoneal dialysis.